# Pregnancy Tests for Family Planning

Kate H. Rademacher, FHI 360 Tracey Brett, FHI 360 David Jenkins, FHI 360 John Stanback, FHI 360

October 13, 2016



10-14 OCTOBER 2016

**#RHSUPPLIES2016** 









receive the contraceptive method. Another obstacle to use of IUCDs and injectable and implantable contraceptives is delaying the start until the menstrual period begins—even sometimes limited to a specific day. In truth, these methods can be started any time if non-pregnancy is established.

-"Medical Barriers to Access to Family Planning" Shelton, Angle and Jacobstein, Lancet, 1992

It appeared that some providers gave methods only to women who were menstruating. Seven of 35 current or past contraceptive users in the qualitative sample reported either being asked to show proof of menstruation or being told to return during their next period. While 6 women indicated receiving a method on their first visit, at least 7 others reported having to return, sometimes multiple times, mostly because they were not menstruating during the clinic visit or to obtain pregnancy test results. A large proportion (43%) of survey respondents agreed with the statement that the nurse would ask to see their menstrual pad if they went for family planning.

-"Getting to 70%: Barriers to modern contraceptive use for women in Rwanda" Brunie, Tolley, Ngabo, Wesson, Chen, 2013

Menstrual
Status as a
Barrier to
Access –
Then and Now

# 66

When you get there, they ask if you are having your period. When it is 'no,' they give you another appointment. When it is 'yes,' they give you cotton wool and you go somewhere discreet to put some blood [on it] and come back to show it to the provider. It is only then that the provider shows you the methods. 49-YEAR-OLD DMPA USER, RWANDA

55

- Lack of menstruation a barrier to contraceptive service delivery providers use menses to rule out pregnancy; clients turned away for same-day FP services
- Many new family planning clients are not menstruating when they visit the clinic
- Few non-menstruating clients are actually pregnant
- According to WHO, no known harm occurs to either a pregnant woman or a fetus from exposure to hormonal family planning methods\*

# What does the evidence tells us?



<sup>\*</sup>In case of the IUD, it is important to rule out pregnancy because inserting an IUD in a woman who is already pregnant may result in septic miscarriage, which is a serious complication.


#### As of 2006...

- The Pregnancy Checklist was adopted in at least 15 countries and available in five language (English, Spanish, French, Romanian, and Kiswahili)
- Included in the Global Handbook for Family Planning and the WHO Decision-Making Tool

#### However...

- There are instances when the checklist cannot exclude pregnancy
- Some providers don't like/ trust the checklist

# The Pregnancy Checklist— Then and Now



Pregnancy tests complement Pregnancy Checklist


Pregnancy tests available for purchase for ≤ US\$0.10

#### Additional benefits:

- FP demand generation
- Social marketing
- Tool for improving continuation of progestinonly methods
- Contribute to decrease in gestational age for clients seeking ANC and abortion services

### Pregnancy Tests: Research in Zambia (FHI 360)

### % New, Non-Menstruating Clients Denied Effective Method







# 2015 Innovation Fund project: Price of 'least expensive' pregnancy test available in US dollars by facility type


		Mali (n=30)	Malawi (n=39)	Kenya (n=42)
Private	mean* [range], US\$	<b>1.99</b> [0.41-3.28]	<b>0.95</b> [0.35-1.77]	<b>1.94</b> [0.98-5.87]
	sample size	n=14	n=19	n=20
	No charge for test	(n=1)	(n=2)	(n=5)
Public	mean* [range], US\$	<b>1.72</b> [0.82-2.46]	<b>0.35</b> [0.35-0.35]	<b>1.86</b> [0.98-4.89]
	sample size	n=10	n=9	n=15
	no charge for test	(n=1)	(n=8)	(n=10)
Pharmacy / Drug shop	mean* [range], US\$	<b>2.12</b> [1.15-2.46]	<b>0.66</b> [0.35-0.88]	<b>0.84</b> [0.49-1.96]
	sample size	n=6	n=11	n=7
	no charge for test	(n=0)	(n=0)	(n=0)

<sup>\*</sup>Mean calculated among facilities that reported charging for the test. Reflects the "least expensive" pregnancy test available at each facility





## Innovation Fund Project: Are Women Ever Sent Away to Buy Tests? (Public & private facilities only)




**Results from following question:** "If there are either occasional stock-outs of pregnancy tests or if pregnancy tests are never available at this facility, are women ever instructed to purchase pregnancy tests elsewhere?





# Innovation Fund Project: Awareness, availability and use of Pregnancy Checklist (public & private facilities)









### New Clinical Job Aid for Providers – When to Use Checklist versus Pregnancy Tests

Figure 2. Job Aid for Ruling Out Pregnancy Prior to Contraceptive Initiation



### FP Clients by Menstrual Status



- International procurement is split across a number of buyers — relatively 'low volume and low value,' which often translates into no dedicated resourcing for quality assurance, limited sharing of information and pooling of resources
- Through the 2015 RHSC Innovation Fund project, stakeholders highlighted a number of concerns related to quality:
  - concerns about fake, counterfeit and questionable CE-marked products entering markets
  - uncertainty and confusion around quality assurance standards
  - limited regulatory approval/oversight
  - limited visibility for procurers on the supply side

New Guidance
Document for
Procurement of
Pregnancy Tests

# 66

We cannot give you the data of how many [inaccurate results]. There is quite a bit that goes on. This is really an area of concern for us....



Interview with Kenya Medical Laboratory Technicians and Technologist Board (KMLTTB) official, Kenya

# Guidance Document For Procurement of Pregnancy Tests: Scope of Project

FHI 360 with USAID funding through the *Envision FP* project, and in consultation with RHSC MDAWG workstream and expert procurement committee, are developing a guidance document for procurers of pregnancy tests.


### Goals:

- Factor in best practices from a number of key documents describing global standards and performance criteria for rapid in vitro diagnostics.
- Broadly outline requirements for quality standards and provide details on technical specifications to optimize the selection of high quality pregnancy tests


### Intended audience:

Individuals responsible for the procurement, supply, and quality assurance of pregnancy test kits at a global, national and/or local level including procurement officers, health officers and supply chain managers responsible for selecting, procuring or assisting in the procurement of pregnancy tests for use in the public and private sectors.


### **Pregnancy Tests: Areas of Guidance Covered**




## Pregnancy Tests - Best Practice, Acceptable Practice & Current General Status



## Pregnancy Tests – Checklist and Tools for Procurers





clean cup/tube -> Dip the dipstick in urine

up to the line indicated by arrows (A) for

the specified period of time  $\rightarrow$  Place the

dipstick flat on a surface, with the result

window facing up, for the specified period

of time for results to develop

Includes a number of useful tools for procurers

### Pregnancy Tests - QA Work Instructions

- Goal to develop work instructions for QA of specificity, sensitivity, accuracy, and package seal integrity
- Intended audience: any laboratory interested in evaluating pregnancy tests (i.e., Africa, Asia, and South America)
- Information obtained from publically available sources, and not from proprietary sources (i.e., manufacturers / suppliers)
- Sampling plans / criteria for different scenarios:
  - product qualification
  - pre-shipment testing
  - post-shipment testing
  - stability study evaluations

### Pregnancy Tests - QA Work Instructions

Overall Sampling Plans and Specifications for Different Testing Scenarios							
Assumed Lot size (35,000 – 150,000)	Product Qualification	Large Scale	Pre / Post / Stability Time Point	Small Scale			
<u>Category 1</u> (Performance)	120 total	Sensitivity – ≥ 95% positive	28 units at high conc.	<u>Sensitivity</u> – ≥ 95% positive			
Positive Controls (hCG x 6)	120 total units	Specificity – Accept ≤ 3 failures	20 units at label claim	<b>Specificity</b> – Accept ≤ 1 failure			
Negative Controls (Blank + interferences)	80 total units	Accuracy – % of true pos./neg. per number tested	16 Blank & 16 Glucose	Accuracy – % of true pos./neg. per number tested			
Category 2 – Package Integrity	32 units	Accept ≤ 2 failures	13 units	Accept ≤ 1 failure			